sorafenib has been researched along with norcantharidin in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (norcantharidin) | Trials (norcantharidin) | Recent Studies (post-2010) (norcantharidin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 272 | 0 | 188 |
| Protein | Taxonomy | sorafenib (IC50) | norcantharidin (IC50) |
|---|---|---|---|
| PPP5C protein, partial | Homo sapiens (human) | 2.567 | |
| serine/threonine-protein phosphatase PP1-alpha catalytic subunit isoform 3 | Homo sapiens (human) | 2.832 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| El Gayar, AM; El-Magd, NFA; Yousef, EH | 1 |
| Feng, YP; Gou, JX; He, HB; Liu, BY; Liu, ZX; Tang, X; Wang, P; Wang, QQ; Wang, YJ; Yin, T; Zhang, Y | 1 |
2 other study(ies) available for sorafenib and norcantharidin
| Article | Year |
|---|---|
Norcantharidin potentiates sorafenib antitumor activity in hepatocellular carcinoma rat model through inhibiting IL-6/STAT3 pathway.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Interleukin-6; Liver Neoplasms; Male; Rats; Sorafenib | 2023 |
Intratumoral injection of norcantharidin liposome emulsion hybrid delivery system amplifies the cancer-fighting effects of oral sorafenib against hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Emulsions; Humans; Injections, Intralesional; Liposomes; Liver Neoplasms; Sorafenib | 2023 |